在炎症性肠道疾病的替代疗法中使用虫
Himani Pandey1, Daryl W T Tang2, Sunny H Wong3
1Redcliffe Labs, Noida, India.
Intestinal research
|February 7, 2025
概括
虫疗法通过调节免疫系统和肠道细菌来治疗炎症性肠病 (IBD) 是有前途的. 虽然需要更多的研究,但目前的研究表明,它是IBD患者的安全和耐受选择.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 寄生虫学的寄生虫学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩氏病和性结肠炎,涉及慢性胃肠道炎症.
- 目前IBD治疗方法有限,许多患者仍然对现有疗法不耐药.
- 虫治疗因其免疫调节性质而成为一种潜在的替代方案.
研究的目的:
- 审查虫疗法的潜力,作为IBD的新疗法.
- 总结有关IBD的虫的免疫调节机制.
- 根据现有的临床和临床前研究,评估虫治疗的安全性和有效性.
主要方法:
- 审查现有的关于虫治疗IBD的文献.
- 对研究虫诱导的免疫反应 (Th2,Treg细胞,细胞因子) 的研究分析.
- 对各种虫物种 (如Trichuris,Schistosoma) 的临床前和临床数据的检查.
主要成果:
- 虫具有免疫调节作用,包括诱导Th2和T调节细胞反应.
- 研究表明,治疗在临床环境中是安全和耐受的.
- 动物模型和一些临床试验表明IBD的潜在治疗益处.
结论:
- 头治疗为管理IBD提供了一个有希望的途径,可能作为替代或辅助治疗.
- 进一步的研究是有必要的,以建立有效性的具体证据和优化治疗方案.
- 虫的免疫调节和微生物群改变能力为IBD管理提供了一种新的方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
100
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
306
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
306
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


